TGFB1 and breast cancer: Indeed, it is well‐established that TGF‐β is crucial for development of bone metastases in vivo[38] and small molecule TGF‐β inhibitors as adjuvant therapy have been shown to reduce EMT in a mouse model metastatic breast cancer[39] with the prospect that further inhibition could shut down this mechanism.